A meta-analysis In patients with COVID-19 and systemic JAK inhibitors (mainly Baricitinib) showed that they probably decrease 28-day all‐cause mortality (95 of 1000 participants in the intervention group versus 131 of 1000 participants in the control group; risk ratio (RR) 0.72, 95% confidence interval (CI) 0.57 to 0.91; 6 studies, 11,145 participants; moderate‐certainty evidence), and decrease 60-day all‐cause mortality (125 of 1000 participants in the intervention group versus 181 of 1000 participants in the control group; RR 0.69, 95% CI 0.56 to 0.86; 2 studies, 1626 participants; high‐certainty evidence).
top of page
General Critical Care
Public·1319 members
Members
bottom of page